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1  | INTRODUC TION
Human epidermal growth factor receptor 2 (HER2) is one of the 
receptor tyrosine kinases (RTK) and a member of the ErbB fam-
ily of proteins. HER2 is activated by homodimerization, or by 
heterodimerization with other receptors of the ErbB family, such 
as epidermal growth factor receptor (EGFR), HER3 and HER4, and 
induces activation of downstream signaling pathways, such as the 
PI3K-AKT and MAPK signaling pathways, promoting cell prolifera-
tion and survival.1 Thus, overexpression of HER2 is considered to be 
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Abstract
Molecular-targeted therapies directed against human epidermal growth factor re-
ceptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan-HER 
tyrosine kinase inhibitor and has been approved by the FDA as an effective drug 
for HER2-positive breast cancer. However, acquired resistance of various cancers to 
molecular-targeted drugs is an issue of clinical concern, and emergence of resistance 
to neratinib is also considered inevitable. In this study, we established various types 
of neratinib-resistant cell lines from HER2-amplified breast and lung cancer cell lines 
using several drug exposure conditions. We analyzed the mechanisms of emergence 
of the resistance in these cell lines and explored effective strategies to overcome the 
resistance. Our results revealed that amplification of YES1, which is a member of the 
SRC family, was amplified in two neratinib-resistant breast cancer cell lines and one 
lung cancer cell line. Knockdown of YES1 by siRNA and pharmacological inhibition of 
YES1 by dasatinib restored the sensitivity of the YES1-amplified cell lines to neratinib 
in vitro. Combined treatment with dasatinib and neratinib inhibited tumor growth in 
vivo. This combination also induced downregulation of signaling molecules such as 
HER2, AKT and MAPK. Our current results indicate that YES1 plays an important role 
in the emergence of resistance to HER2-targeted drugs, and that dasatinib enables 
such acquired resistance to neratinib to be overcome.
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the oncogenic driver in several malignancies, including breast, lung, 
gastric, ovarian and esophageal cancers.2-4
There have been substantial advances in the development of HER2-
targeted therapies for HER2-overexpressing cancers. HER2-targeted 
drugs include trastuzumab, pertuzumab, lapatinib and trastuzumab 
emtansine (T-DM1). However, acquired resistance to trastuzumab or 
lapatinib has been reported in cases of breast cancer.5,6 Acquired resis-
tance to trastuzumab in cases of gastric cancer has also been reported.7 
Therefore, overcoming acquired resistance to HER2-targeted therapies 
is a major clinical challenge in the treatment of HER2-positive cancers.
Neratinib (HKI-272) is an irreversible EGFR, HER2 and HER4 
tyrosine kinase inhibitor (TKI),8 which has been reported to im-
prove the overall survival in postoperative HER2-positive breast 
cancer patients who have previously received trastuzumab-based 
adjuvant therapy.9 Many trials of the efficacy of neratinib for 
other types of cancers are also ongoing. Previously, we reported 
the antitumor effect of neratinib against lung cancer harboring 
HER2 oncogene alterations.10 Moreover, it was reported that ne-
ratinib could be used to overcome trastuzumab resistance in cases 
of breast cancer.11 However, emergence of resistant cancer cells 
during the course of treatment with small-molecule inhibitors is 
well known. Therefore, development of resistance to neratinib is 
strongly predicted.
In this study, we established neratinib-resistant cells from the 
HER2-amplified breast cancer cell line BT-474 and the HER2-amplified 
lung cancer cell line NCI-H2170 (H2170). Then, we elucidated the 
mechanism of emergence of acquired resistance to neratinib and ex-
plored therapeutic strategies to overcome the resistance.
2  | MATERIAL S AND METHODS
2.1 | Cell lines and reagents
The breast cancer cell line BT-474 and the lung cancer cell line H2170 
were used in this study. The cell lines were purchased from the ATCC. 
Neratinib-resistant sublines were established from the BT-474 and 
H2170 cell lines using the following procedures: cells were exposed 
to neratinib with stepwise escalation of the dose from 1 nmol/L to 
2 μmol/L over 6 months (stepwise escalation method), or the cells were 
exposed to 2 µmol/L of neratinib from the start of the culture (high 
concentration method). Neratinib-resistant sublines established by the 
stepwise escalation method were designated by the name of the pa-
rental cell line, followed by “-NRS” and those established by the high 
concentration method were designated by the name of the parental 
cell line followed by “-NRH”. If two neratinib-resistant breast cancer 
sublines were established independently using the same method, the 
established cell lines were distinguished by adding a number to their 
names (eg, BT-474-NRS and BT-474-NRS2). All the cell lines were au-
thenticated by short tandem repeat (STR) DNA analysis (Promega). All 
the breast cancer cell lines were cultured in DMEM containing 10% FBS 
and all the lung cancer cell lines were cultured in RPMI-1640 medium 
containing 10% FBS under 5% CO2 at 37°C. Neratinib was purchased 
from Selleck Chemicals. Dasatinib was purchased from Bristol-Myers 
Squibb.
2.2 | Cell viability assay
The antitumor effects of the drugs were determined by MTS assay in vitro. 
Cells (3000/well) were seeded on a 96-well plate, and then serial dilutions 
of the drugs were added 24 hours later. The cells were incubated in the 
presence of the drugs for 72 hours under 5% CO2 at 37°C. Cell viability 
was determined by CellTiter 96 AQueous One Solution Cell Proliferation 
Assay (Promega). The optical densities of the samples were measured 
at 492 nm using a Multiskan FC Microplate Photometer (Thermo Fisher 
Scientific). The antitumor effect of each drug was expressed as the inhibi-
tory concentration at 50% (IC50). The assays were repeated three times. 
Data were expressed as the mean ± standard error (SE).
2.3 | Western blotting
Cells were washed in ice-cold PBS and lysed with lysis buffer, a mixture 
of RIPA buffer, phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich) 
and Complete Mini (Roche). The cell lysate was collected after centrifu-
gation at 20 000 g for 15 minutes at 4°C. Protein was quantified using 
the DC Protein Assay Kit (Bio-Rad Laboratories), fractionated on SDS-
PAGE and blotted onto a membrane using the Trans-Blot Turbo Transfer 
System (Bio-Rad Laboratories). After the membrane was blocked with 
5% skim milk in TBS-containing 0.05% Tween 20 (T-TBS) for 1 hour, it 
was probed with the primary antibody overnight at 4°C, followed by in-
cubation with the secondary antibody for 1 hour at 25°C. Proteins were 
detected using ECL Prime Western Blotting Detection Reagent (General 
Electric Company) and by scanning the membrane using ImageQuant 
LAS 4000 (General Electric Company). The primary antibodies used 
were as follows: phospho-HER2-Tyr877, HER2, phospho-AKT-Ser473, 
AKT, phospho-MAPK-Tyr202/204, MAPK, phospho-SRC family-Tyr416, 
YES1, cleaved PARP (Cell Signaling Technology) and Actin (used as the 
loading control) (Merck Millipore). The secondary antibody was HRP-
conjugated anti–mouse or anti–rabbit IgG (Santa Cruz Biotechnology).
2.4 | Copy number assay
Genomic DNA was extracted from the cell lines using the DNeasy 
Blood & Tissue Kit (Qiagen). The copy number was determined with 
the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) 
using Taqman copy number assays (Thermo Fisher Scientific). 
TaqMan RNase P Control (Thermo Fisher Scientific) was used as 
the reference gene. The relative copy number in each sample was 
determined by comparing the ratio of the Ct value of the target 
gene to that of the reference gene in each sample with the ratio in 
standard genomic DNA (Merck), after validating that the efficiencies 
of the PCR reactions of both the target and reference genes were 
equal. The gene copy number in standard genomic DNA was set at 2. 
     |  851TAKEDA ET Al.
Samples were analyzed in triplicate. The assays were repeated three 
times. Data were expressed as mean ± SE.
2.5 | Gene expression assay
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and re-
verse-transcribed with the High Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific). Quantitative RT-PCR (qRT-PCR) was 
performed on the StepOnePlus Real-Time PCR System (Thermo Fisher 
Scientific) using TaqMan Gene Expression Assays (Thermo Fisher 
Scientific). The gene expression level was calculated using the delta-
delta CT method. GAPDH was used as the endogenous control. The 
assays were repeated three times. Data were expressed as mean ± SE.
2.6 | siRNA transfection
siRNA specific for YES1 (Silencer1 Select Validated siRNA 
#4390824) and the non-targeting control (Silencer1 Select Negative 
Control No. 2 siRNA #4390846) were purchased from Thermo 
Fisher Scientific. Each siRNA (5 nmol/L of the dose) was trans-
fected to the cells using Lipofectamine RNAiMAX Transfection 
Reagent (Thermo Fisher Scientific). After the siRNA transfection, 
the cells were incubated for 72 hours under 5% CO2 at 37°C.
2.7 | Co–immunoprecipitation
Protein lysates were immunoprecipitated with anti–HER2 antibody 
(Cell Signaling Technology) or normal mouse IgG (Santa Cruz) using 
Dynabeads Protein G (Thermo Fisher Scientific), in accordance with 
the manufacturer's instructions.
2.8 | Xenograft mouse model
Six-week-old BALB/c-nu/nu female mice were purchased from 
Charles River Laboratories (Yokohama, Japan). All mice were 
provided with sterilized food and water and housed in a barrier facil-
ity under a 12:12-hour light-dark cycle. BT-474-NRS2 (107 cells) was 
suspended in 100 μL of DMEM with Matrigel Basement Membrane 
Matrix (Corning) mixture (1:1 ratio) and injected subcutaneously into 
the backs of the mice. Tumors were measured using digital calipers, 
and the tumor volumes were calculated using the formula: vol-
ume = 1/2 × [(shortest diameter)2 × (the longest diameter)]. When 
the tumor volumes exceeded approximately 150 mm3, the mice were 
randomly allocated to one of four groups: a control group, a neratinib 
(10 mg/kg/d) group, a dasatinib (15 mg/kg/d) group and a neratinib 
(10 mg/kg/d) plus dasatinib (15 mg/kg/d) group (n = 6 per group). 
The drugs were suspended in 0.5 w/v (%) methyl cellulose and ad-
ministered by oral gavage five times a week for 4 weeks. The tumor 
volumes were measured twice a week. Data were expressed as 
mean ± SE. The protocol was approved by the Animal Care and Use 
Committee, Okayama University (Permit Number: OKU-2019328).
2.9 | Statistical analysis
All the statistical analyses in this study were performed using EZR 
version 1.40 (Saitama Medical Center, Jichi Medical University, 
Saitama, Japan), which is a graphical user interface for R version 
3.5.2 (The R Foundation for Statistical Computing, Vienna, Austria).12 
Specifically, the software is a modified version of R commander de-
signed to add statistical functions frequently used in biostatistics. 
Differences were compared using one-way analysis of variance (mul-
tiple groups) or the t test (two groups). P < 0.05 was considered as 
being indicative of statistical significance.
3  | RESULTS
3.1 | Establishment of neratinib-resistant cell lines
The breast cancer cell line BT-474 and lung cancer cell line H2170 
with HER2 amplification were exposed to neratinib using two differ-
ent methods: the stepwise escalation method (NRS series) and the 
high concentration method (NRH series). The parent cell lines are 
Cancer type Cell line
Method of drug 
exposure
Neratinib IC50
Mean ± standard error (μmol/L)
Breast BT-474 — 0.0028 ± 0.00019
BT-474-NRS Stepwise 0.97 ± 0.18
BT-474-NRS2 Stepwise 1.45 ± 0.25
BT-474-NRH High 1.69 ± 0.35
BT-474-NRH2 High 1.44 ± 0.26
Lung H2170 — 0.029 ± 0.0059
H2170-NRS Stepwise >10
H2170-NRH High 3.96 ± 0.49
-, not applicable. 
TA B L E  1   IC50 values for neratinib 
and the methods of drug exposure in 
neratinib-resistant cell lines
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known to be highly sensitive to neratinib. As a result, we obtained six 
neratinib-resistant cell lines: BT-474-NRS, BT-474-NRS2, BT-474-
NRH, BT-474-NRH2, H2170-NRS and H2170-NRH.
The IC50 values of neratinib are shown in Table 1. The IC50 values 
of neratinib for these six resistant cell lines were at least 100-fold 
the values for the parental cell lines.
3.2 | Status of human epidermal growth factor 
receptor 2 and human epidermal growth factor receptor 
2-related signaling in the neratinib-resistant cell lines
We evaluated the expression and phosphorylation levels of the HER2-
related signaling molecules (Figure 1A). Both BT-474-NRS and BT-
474-NRS2 showed elevated phosphorylation levels of HER2 and AKT. 
BT-474-NRH, BT-474-NRH2, H2170-NRS and H2170-NRH showed 
downregulated expression of HER2. Then, we evaluated the copy 
number and mRNA expression of HER2 (Figure S1); the copy number 
and mRNA expression of HER2 seemed to be decreased, as compared 
to those in the parental cell lines, in H2170-NRS and H2170-NRH.
3.3 | YES1 upregulation in neratinib-resistant 
cell lines
We previously reported that YES1, a member of the SRC family, plays an 
important role in the emergence of acquired resistance of HER2-positive 
breast cancer to trastuzumab and lapatinib.13 Therefore, we investigated 
the expression levels of YES1. Both the expression levels of YES1 and 
the phosphorylation levels of the SRC family proteins were upregulated 
in BT-474-NRS, BT-474-NRS2 and H2170-NRH (Figure 1A). We also 
determined the copy number of YES1, which revealed gain of the copy 
number in BT-474-NRS, BT-474-NRS2 and H2170-NRH (Figure 1B).
3.4 | Effect of YES1 knockdown in the neratinib-
resistant cell lines
To clarify the effect of YES1 in BT-474-NRS, BT-474-NRS2 and H2170-
NRH, we performed YES1 knockdown using siRNA and confirmed that the 
antitumor effect of neratinib was restored in the resistant cell lines after 
YES1 knockdown (Figure 2A). We performed Western blot analysis to inves-
tigate the effect of YES1 knockdown on the HER2-related signaling path-
ways. Phosphorylation of the SRC family proteins was suppressed by YES1 
knockdown in the resistant cell lines. Furthermore, a greater degree of inhi-
bition of the phosphorylation of HER2, AKT and MAPK was observed with 
the combination of YES1 knockdown and neratinib than with either alone 
(Figure 2B). Furthermore, phosphorylation of HER2 was also suppressed by 
YES1 knockdown. To identify the interaction between HER2 and YES1, we 
performed a co–immunoprecipitation (IP) assay, which revealed that YES1 
was bound to HER2 in BT-474-NRS and BT-474-NRS2 (Figure S2).
3.5 | Effect of dasatinib in the neratinib-resistant 
cell lines
We focused on the SRC inhibitor dasatinib because YES1, one 
of the members of the SRC family proteins, was upregulated 
in BT-474-NRS, BT-474-NRS2 and H2170-NRH. We used the 
F I G U R E  1   YES1, a member of the SRC family, is amplified and overexpressed in neratinib-resistant cell lines. A, Protein expression and 
phosphorylation profile of neratinib-resistant breast cancer and lung cancer cell lines. B, Copy number assay of YES1 in (i) BT-474, BT-474-
NRS, BT-474-NRS2, (ii) H2170 and H2170-NRH. Human genomic DNA (HGD) was used as the control (two copies). The assay was repeated 
three times. Data are shown as mean ± standard error
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combination of neratinib plus dasatinib to overcome the resist-
ance to neratinib. The combination of neratinib and dasatinib 
exerted remarkable antitumor effects against the resistant cell 
lines (Figure 3A). We also performed western blot analysis to elu-
cidate the effect of the combination therapy. In the resistant cell 
lines, phosphorylations of HER2, AKT and MAPK were inhibited 
to a greater extent by the combination of neratinib plus dasatinib 
than by either drug alone, similar to the case for the combination 
of YES1 knockdown plus neratinib (Figure 3B). We evaluated the 
presence of apoptosis by analyzing the amount of cleaved PARP, 
an apoptosis marker, and revealed that apoptosis was also in-
duced by the combination of neratinib plus dasatinib (Figure 3C).
Furthermore, based on the results of in vitro assays, we per-
formed an in vivo assay to examine the effect of the combination of 
neratinib plus dasatinib using BT-474-NRS2. The tumor growth was 
significantly suppressed in the combination therapy group as com-
pared to the control group (Figure 3D). No significant differences 
were observed in the body weights of the treated mice (Figure S3).
F I G U R E  2   YES1 knockdown overcomes neratinib resistance. A, MTS assay to assess the sensitivity to neratinib of (i) BT-474, (ii) BT-474-
NRS, (iii) BT-474-NRS2, (iv) H2170 and (v) H2170-NRH after YES1 knockdown. Cells were transfected with siRNA followed by treatment 
with neratinib for 72 h. The assay was repeated three times. Data are shown as mean ± SE; *P < 0.05, **P < 0.01 vs negative control (siNEC). 
B, Effect of YES1 knockdown on the protein expression and phosphorylation profiles in the presence/absence of neratinib treatment in (i) 
BT-474, BT-474-NRS, BT-474-NRS2, (ii) H2170 and H2170-NRH. The cells were treated with neratinib for 2 h after the siRNA transfection
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4  | DISCUSSION
In this study, we established six neratinib-resistant cell lines from 
two HER2-amplified cell lines. Two methods were used to estab-
lish the resistance, the stepwise escalation method and the high 
concentration method, based on our previous report that the condi-
tion of EGFR-TKI exposure influenced the mechanism of emergence 
of acquired resistance in lung cancer cell lines.14 Clinically, the re-
ported mean trough plasma concentration of neratinib in patients 
after once-daily oral administration of the drug at the dose of 240 mg 
F I G U R E  3   Dasatinib, an SRC family inhibitor, enables the resistance to neratinib to be overcome. A, MTS assay to assess the effect of 
neratinib alone, dasatinib alone and the combination of neratinib plus dasatinib on (i) BT-474, BT-474-NRS, BT-474-NRS2, (ii) H2170 and 
H2170-NRH. The cells were treated with the drugs for 72 h. The assay was repeated three times. Data are shown as mean ± standard error. 
B, Effect of neratinib alone, dasatinib alone and the combination of neratinib plus dasatinib on protein phosphorylation in (i) BT-474, BT-
474-NRS, BT-474-NRS2, (ii) H2170 and H2170-NRH. The cells were treated with the drugs for 2 h. C, Apoptosis assay by detection of PARP 
cleavage in (i) BT-474, BT-474-NRS, BT-474-NRS2, (ii) H2170 and H2170-NRH. The cells were treated with neratinib alone, dasatinib alone 
or the combination of neratinib plus dasatinib for 48 h. D, Growth of BT-474-NRS2 in BALB/c nude mice. The mice were given neratinib 
(10 mg/kg) alone, dasatinib (15 mg/kg) alone or the combination of neratinib plus dasatinib by oral gavage five times a week. Data are shown 
as mean ± SE (n = 6)
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is 52-59 ng/mL (0.093-0.106 μmol/L).15 The IC50 values of neratinib 
for neratinib-resistant cell lines were sufficiently high. Therefore, we 
considered that the neratinib-resistant cell lines established by us 
were sufficiently resistant to neratinib.
Activation of CYP3A4 has been reported as one of the mech-
anisms underlying the development of resistance to neratinib, and 
resistance to neratinib conferred cross-resistance to trastuzumab, 
lapatinib and afatinib.16 In our study, we found amplification of YES1 
in BT-474-NRS, BT-474-NRS2 and H2170-NRH. YES1 is a member 
of the SRC family of proteins, which are non–receptor tyrosine ki-
nases.17 The SRC family proteins include c-SRC, YES1, FYN, LYN, 
FGR, BLK, HCK, LCK and FRK, which are key regulators of signal 
transduction.18 Our previous study showed that amplification of 
YES1 was associated with resistance to HER2 inhibitors, such as tras-
tuzumab and lapatinib, in breast cancer13 and afatinib in gastric can-
cer.19 Moreover, YES1 amplification was also found to be associated 
with resistance to EGFR inhibitors in patients with lung cancer.20 
Therefore, our results suggest that YES1 amplification is a mecha-
nism of resistance to not only neratinib, but also to general inhibitors 
of the ErbB family.
We focused on dasatinib (BMS-354825), which is a dual SRC/
ABL kinase inhibitor,21 as a useful drug to overcome resistance to 
neratinib. In clinical settings, dasatinib is used to treat chronic my-
elogenous leukemia and Philadelphia chromosome-positive acute 
lymphoblastic leukemia, targeting the BCR-ABL fusion protein.22 
Dasatinib has also been reported to inhibit YES1.23 In the current 
study, the combination of dasatinib plus neratinib exerted a marked 
antitumor effect against YES1-amplified neratinib-resistant cells, 
both in vitro and in vivo. Furthermore, we reported that this com-
bination therapy was also effective against trastuzumab and tras-
tuzumab/lapatinib-resistant cells harboring YES1 amplification.13 
These results suggest that combined dasatinib plus neratinib treat-
ment should be considered in clinical cases where reassessment of 
the tumor cells after they acquire resistance to HER2-targeted ther-
apies reveals amplification of YES1.
Human epidermal growth factor receptor 2 was more phos-
phorylated in BT-474-NRS and BT-474-NRS2 compared to the 
parental BT-474, whereas HER2 expression was decreased in 
H2170-NRH compared to the parental H2170. Despite this dif-
ference, the combination therapy of neratinib plus inhibition of 
YES1 exerted a remarkable antitumor effect in all these cell lines. 
Phosphorylation of AKT and MAPK was slightly suppressed by 
a single agent of neratinib in BT-474-NRS, BT-474-NRS2 and 
H2170-NRH, as shown in Figure 3B. Their phosphorylation might 
have been reduced due to the suppression of not only HER2 but 
also EGFR and/or HER4, because neratinib is a pan-HER inhibitor. 
It is highly possible that BT-474-NRS and BT-474-NRS2 depend on 
HER2 because the phosphorylation of HER2 was promoted com-
pared to the parental BT-474. In contrast, EGFR and/or HER4 path-
way might be activated rather than HER2 in H2170-NRH because 
the expression and phosphorylation of HER2 was decreased in 
H2170-NRH compared to the parental H2170. Although whether 
or not BT-474-NRS, BT-474-NRS2 and H2170-NRH still depend 
on HER2 has not been clarified, inhibition of YES1 results in over-
coming the neratinib resistance in the cells harboring YES1 ampli-
fication regardless of HER2 expression status.
We revealed previously that cancer stem cell (CSC)-like fea-
tures and epithelial-to-mesenchymal transition (EMT) were in-
volved in the resistance of lung cancer to ErbB family-TKI.14,24,25 
Therefore, we also investigated the expression levels of the CSC 
markers and EMT markers in the resistant cell lines. ALDH1A1 is a 
putative CSC marker, and we found overexpression of ALDH1A1 
in BT-474-NRH and BT-474-NRH2 (Figure S4). N-cadherin and vi-
mentin, which are EMT markers, were not detected in any of the 
resistant cell lines (data not shown). CSC-like features were also 
found in the neratinib-resistant cell lines. Development of a ther-
apeutic strategy against cells with CSC-like features is one of the 
tasks for the future.
Expression of HER2 protein was downregulated in BT-474-NRH, 
BT-474-NRH2, H2170-NRS and H2170-NRH. Clinically, loss of HER2 
amplification has been reported after treatment with trastuzumab in 
patients with breast and gastric cancer.26-28 Moreover, there are some 
reports from vitro studies which suggest downregulated expression 
of HER2 protein in a neratinib-resistant breast cancer cell line and 
a decrease of the copy number of HER2 in an afatinib-resistant lung 
cancer cell line.16,24 Reduction of HER2 protein expression may be 
one of the factors contributing to the resistance to HER2 inhibitors, 
because it results in a decrease in the amount of the drug target.
Phosphorylation of HER2 was suppressed by a single agent of 
YES1 knockdown or dasatinib treatment. This is consistent with our 
observation in a previous study.13 According to other reports, this 
phenomenon was also observed with saracatinib (AZD-0530) (a 
SRC/ABL inhibitor) treatment in trastuzumab-resistant breast can-
cer and gastric cancer.29,30 It has been reported that SRC interacts 
with HER2.17 Therefore, we proposed a hypothesis that YES1 may 
also interact with HER2. We performed co–IP assay to clarify the 
interaction of YES1 with HER2 and demonstrated that YES1 bound 
directly with HER2. Thus, YES1 may bind to and activate HER2. 
Further studies are necessary for obtaining a better understanding.
In conclusion, we found that YES1 played an important 
role in the emergence of resistance to HER2-targeted drugs. 
Furthermore, the combination therapy of dasatinib plus neratinib 
enabled the resistance to neratinib to be overcome. These find-
ings are expected to contribute to improvement of the therapeutic 
outcomes in patients with breast cancer or lung cancer harboring 
HER2 amplification.
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